Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04496349 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
A Phase 2 study of Non-Hodgkin's Lymphoma and T-Prolymphocytic Leukemia, sponsored by Ascentage Pharma Group.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
- 1
- Study location
NCT04496349: Recruiting Phase 2 study of Non-Hodgkin's Lymphoma and T-Prolymphocytic Leukemia, sponsored by Ascentage Pharma Group.
NCT04496349 is a Phase 2 study of Non-Hodgkin's Lymphoma and T-Prolymphocytic Leukemia that is actively recruiting participants, run by Ascentage Pharma Group. The registered enrollment target is 78 participants, below the 220-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04496349, a Phase 2 study of Non-Hodgkin's Lymphoma and T-Prolymphocytic Leukemia, is actively recruiting participants, sponsored by Ascentage Pharma Group.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to evaluate the pharmacokinetics (PK), safety, and efficacy of APG-115 as a single agent or in combination with APG-2575 in patients with T-PLL and NHL.
Primary Outcome
To evaluate the safety of APG-115 as a single agent
Conditions Studied
Interventions
- DRUG APG-2575
- DRUG APG-115
Study Locations (1)
Texas
- MD Anderson - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2021-07-12 |
| Est. Completion | 2027-05-31 |
| Phase | Phase 2 |
What NCT04496349 shows while recruiting
NCT04496349 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 220-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (65% lower).
The record links to 2 conditions, with Non-Hodgkin's Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which APG-2575 is the first listed.
NCT04496349 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04496349 about?
NCT04496349 is a clinical study titled "A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL". The goal of this study is to evaluate the pharmacokinetics (PK), safety, and efficacy of APG-115 as a single agent or in combination with APG-2575 in patients with T-PLL and NHL.
What is the current status of trial NCT04496349?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2021-07-12. Estimated completion is 2027-05-31.
What conditions does trial NCT04496349 study?
This clinical trial studies the following conditions: Non-Hodgkin's Lymphoma, T-Prolymphocytic Leukemia.
What interventions are being tested in trial NCT04496349?
The interventions under investigation include: APG-2575 (DRUG), APG-115 (DRUG).
Who is sponsoring clinical trial NCT04496349?
This trial is sponsored by Ascentage Pharma Group, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04496349 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin's Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04496349's enrollment target sits among peer trials
78 23rd of 63 higher than 41 of 63 other Non-Hodgkin's Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Hodgkin's Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cord Blood Transplant in Adults With Blood Cancers
RECRUITING · Phase 2
-
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
RECRUITING · Phase 2
-
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
RECRUITING · Phase 2
-
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas
ACTIVE NOT RECRUITING · Phase 2
-
Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI